Lixisenatide
Vertex buys Alpine Immune Sciences for US$ 4.9 billion; Merck KGaA signs ADC deal with AI biotech Caris

Vertex buys Alpine Immune Sciences for US$ 4.9 billion; Merck KGaA signs ADC deal with AI biotech Caris

This week’s Phispers comes packed with deals, approvals and trial wins. Vertex Pharmaceuticals has decided to bet big on ...

Impressions : 2108